Press Release

Agenus R&D Update to Be Held on November 19, 2015

November 12, 2015

LEXINGTON, Mass.--()--Agenus Inc. (NASDAQ: AGEN), today announced additional details for the Company’s upcoming R&D update session to be held on Thursday, November 19, 2015, from 4:00 to 7:00 PM Eastern Time at the:

St. Regis Hotel
Two East 55th Street at Fifth Avenue
New York, NY

The event will provide an overview of Agenus’ recent strategic transactions and progress with its pipeline, including its checkpoint modulator programs and heat shock protein-based vaccine Prophage™.

The event will be moderated by Garo Armen, PhD, Chief Executive Officer and Robert Stein, MD, PhD, Chief Scientific Officer of Agenus and Head of Research and Development, and will include presentations by key members of the research management followed by a discussion.


Agenus presenters will include:


Prior Affiliations

-- John Castle, PhD                                                   BioNTech, AG., Rosetta, Merck
-- Alex Duncan, PhD                                                   Astra Zeneca, Cambridge Antibody Technology
-- Dennis Underwood, PhD                                                   Infinity Pharma, Bristol-Myers Squibb, Merck
-- Marc Van Dijk, PhD                                                   Genmab, Medarex
-- Nicholas Wilson, PhD                                                   EMD Serono, Inc., Novartis, Genentech
-- John Goldberg, MD                                                   UMMSM, Dana-Farber Cancer Institute

A live webcast will be accessible from the Company’s website at A replay of the event will be available on the company’s website.

About Agenus

Agenus is an immunology company engaged in the discovery and development of novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. Using its proprietary platforms Retrocyte Display™ and SECANT®, the Company is discovering and developing novel antibodies to target GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed checkpoints in partnered and internal programs. Agenus’ heat shock protein vaccine, Prophage, has successfully completed Phase 2 studies in newly diagnosed glioblastoma multiforme. The Company’s QS-21 Stimulon® adjuvant is partnered with GlaxoSmithKline and Janssen Sciences Ireland UC. For more information, please visit; information that may be important to investors will be routinely posted on our website.

Forward-Looking Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the Company’s upcoming R&D update. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of Agenus’ Form 10-Q filed with the Securities and Exchange Commission on November 4, 2015. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.



Agenus Inc.
Michelle Linn, 774-696-3803
BMC Communications
Brad Miles, 646-513-3125
Argot Partners
Andrea Rabney, 212-600-1902